Advertisement

Targeted Oncology

, Volume 13, Issue 5, pp 567–582 | Cite as

Treatment of Advanced Merkel Cell Carcinoma: Current Therapeutic Options and Novel Immunotherapy Approaches

  • Daniela Femia
  • Natalie Prinzi
  • Andrea Anichini
  • Roberta Mortarini
  • Federico Nichetti
  • Francesca Corti
  • Martina Torchio
  • Giorgia Peverelli
  • Filippo Pagani
  • Andrea Maurichi
  • Ilaria Mattavelli
  • Massimo Milione
  • Nice Bedini
  • Ambra Corti
  • Maria Di Bartolomeo
  • Filippo de Braud
  • Sara Pusceddu
Review Article

Abstract

Advanced Merkel cell carcinoma (MCC) is a very aggressive, rare neuroendocrine tumor of the skin with a high frequency of locoregional recurrence and metastasis, and a high mortality rate. Surgical resection, sentinel lymph node biopsy, and radiotherapy represent the gold standard of treatment in patients with localized disease, while chemotherapy has a significant role in the treatment of advanced disease. However, no definitive evidence on the survival impact of radiotherapy in the advanced stages has been provided to date, and response to chemotherapy remains brief in the majority of cases, indicating an urgent need for alternative approaches. Biological and genome sequencing studies have implicated multiple molecular pathways in MCC, thus leading to the development of new agents that target angiogenic factors, anti-apoptosis molecules, poly-ADP ribose polymerase, intracellular signal proteins such as the PI3K/AKT/mTOR pathway, and peptide receptors such as somatostatin receptors. More recently, immunotherapy agents such as avelumab, pembrolizumab, and nivolumab, which act by blocking the programmed cell-death (PD)-1/PD-L1 immune checkpoint, have shown promising results, especially in the advanced setting, and should now be considered standard of care for metastatic MCC. Current research is focusing on developing new immunotherapeutic strategies, identifying predictive biomarker to aid in the selection of patients responsive to immunotherapy, and defining combination approaches to increase efficacy in refractory patients.

Notes

Acknowledgments

Editorial assistance in the preparation of this manuscript was provided by Aashni Shah, on behalf of Polistudium (Milan, Italy); this assistance was supported by internal funds. We also thank Lilia Biscaglia, PhD, for useful discussion.

Compliance with Ethical Standards

Funding

No external funding was used in the preparation of this manuscript.

Conflict of Interest

Daniela Femia, Natalie Prinzi, Andrea Anichini, Roberta Mortarini, Federico Nichetti, Francesca Corti, Martina Torchio, Giorgia Peverelli, Filippo Pagani, Andrea Maurichi, Ilaria Mattavelli, Massimo Milione, Nice Bedini, Ambra Corti, Maria Di Bartolomeo, Filippo de Braud, and Sara Pusceddu declare that they have no conflicts of interest that might be relevant to the contents of this manuscript.

References

  1. 1.
    Lemos BD, Storer BE, Iyer JG, Phillips JL, Bichakjian CK, Fang LC, et al. Pathologic nodal evaluation improves prognostic accuracy in Merkel cell carcinoma: analysis of 5823 cases as the basis of the first consensus staging system. J Am Acad Dermatol. 2010;63:751–61.PubMedPubMedCentralCrossRefGoogle Scholar
  2. 2.
    American Cancer Society. Key statistics for Merkel cell carcinoma. 2016. http://www.cancer.org/cancer/skincancer-Merkelcell/detailedguide/skin-cancer-Merkel-cell-carcinoma-key-statistics. Accessed 22 April 2017.
  3. 3.
    Hodgson NC. Merkel cell carcinoma: changing incidence trends. J Surg Oncol. 2005;89:1–4.PubMedCrossRefGoogle Scholar
  4. 4.
    van der Zwan JM, Trama A, Otter R, Larranaga N, Tavilla A, Marcos-Gragera R, et al. Rare neuroendocrine tumours: results of the surveillance of rare cancers in Europe project. Eur J Cancer. 2013;49:2565–78.PubMedCrossRefGoogle Scholar
  5. 5.
    Banks PD, Sandhu S, Gyorki DE, Johnston ML, Rischin D. Recent insights and advances in the management of Merkel cell carcinoma. J Oncol Pract. 2016;12:637–46.PubMedCrossRefGoogle Scholar
  6. 6.
    Schadendorf D, Lebbé C, Zur Hausen A, Avril MF, Hariharan S, Bharmal M, et al. Merkel cell carcinoma: epidemiology, prognosis, therapy and unmet medical needs. Eur J Cancer. 2017;71:53–69.PubMedCrossRefGoogle Scholar
  7. 7.
    Albores-Saavedra J, Batich K, Chable-Montero F, Sagy N, Schwartz AM, Henson DE. Merkel cell carcinoma demographics, morphology, and survival based on 3870 cases: a population-based study. J Cutan Pathol. 2010;37:20–7.PubMedCrossRefGoogle Scholar
  8. 8.
    Koksal Y, Toy H, Talim B, Unal E, Akcoren Z, Cengiz M. Merkel cell carcinoma in a child. J Pediatr Hematol Oncol. 2009;31:359–61.PubMedCrossRefGoogle Scholar
  9. 9.
    Marzban S, Geramizadeh B, Farzaneh MR. Merkel cell carcinoma in a 17-year-old boy, report of a highly aggressive fatal case and review of the literature. Rare Tumors. 2011;3:e34.PubMedPubMedCentralCrossRefGoogle Scholar
  10. 10.
    Toker C. Trabecular carcinoma of the skin. Arch Dermatol. 1972;105:107–10.PubMedCrossRefGoogle Scholar
  11. 11.
    Kotteas EA, Pavlidis N. Neuroendocrine Merkel cell nodal carcinoma of unknown primary site: management and outcomes of a rare entity. Crit Rev Oncol Hematol. 2015;94:116–21.PubMedCrossRefGoogle Scholar
  12. 12.
    Johansson L, Tennvall J, Akerman M. Immunohistochemical examination of 25 cases of Merkel cell carcinoma: a comparison with small cell carcinoma of the lung and oesophagus, and a review of the literature. APMIS. 1990;98:741–52.PubMedCrossRefGoogle Scholar
  13. 13.
    Scott MP, Helm KF. Cytokeratin 20: a marker for diagnosing Merkel cell carcinoma. Am J Dermatopathol. 1999;21:16–20.PubMedCrossRefGoogle Scholar
  14. 14.
    Harms KL, Healy MA, Nghiem P, Sober AJ, Johnson TM, Bichakjian CK, et al. Analysis of prognostic factors from 9387 Merkel cell carcinoma cases forms the basis for the new 8th edition AJCC staging system. Ann Surg Oncol. 2016;23:3564–71.PubMedCrossRefGoogle Scholar
  15. 15.
    Feng H, Shuda M, Chang Y, Moore PS. Clonal integration of a polyomavirus in human Merkel cell carcinoma. Science. 2008;319:1096–100.PubMedPubMedCentralCrossRefGoogle Scholar
  16. 16.
    Agelli M, Clegg LX. Epidemiology of primary Merkel cell carcinoma in the United States. J Am Acad Dermatol. 2003;49:832–41.PubMedCrossRefGoogle Scholar
  17. 17.
    Lanoy E, Dores GM, Madeleine MM, Toro JR, Fraumeni JF Jr, Engels EA. Epidemiology of nonkeratinocytic skin cancers among persons with AIDS in the United States. AIDS. 2009;23:385–93.PubMedPubMedCentralCrossRefGoogle Scholar
  18. 18.
    Lanoy E, Costagliola D, Engels EA. Skin cancers associated with HIV infection and solid-organ transplantation among elderly adults. Int J Cancer. 2010;126:1724–31.PubMedPubMedCentralGoogle Scholar
  19. 19.
    Koljonen V, Kukko H, Tukiainen E, Böhling T, Sankila R, Pukkala E, et al. Incidence of Merkel cell carcinoma in renal transplant recipients. Nephrol Dial Transplant. 2009;24:3231–5.PubMedCrossRefGoogle Scholar
  20. 20.
    Foulongne V, Sauvage V, Hebert C, Dereure O, Cheval J, Gouilh MA, et al. Human skin microbiota: high diversity of DNA viruses identified on the human skin by high throughput sequencing. PLoS One. 2012;7:e38499.PubMedPubMedCentralCrossRefGoogle Scholar
  21. 21.
    Schowalter RM, Pastrana DV, Pumphrey KA, Moyer AL, Buck CB. Merkel cell polyomavirus and two previously unknown polyomaviruses are chronically shed from human skin. Cell Host Microbe. 2010;7:509–15.PubMedPubMedCentralCrossRefGoogle Scholar
  22. 22.
    Kean JM, Rao S, Wang M, Garcea RL. Seroepidemiology of human polyomaviruses. PLoS Pathog. 2009;5:e1000363.PubMedPubMedCentralCrossRefGoogle Scholar
  23. 23.
    Tolstov YL, Pastrana DV, Feng H, Becker JC, Jenkins FJ, Moschos S, et al. Human Merkel cell polyomavirus infection II. MCV is a common human infection that can be detected by conformational capsid epitope immunoassays. Int J Cancer. 2009;125:1250–6.PubMedPubMedCentralCrossRefGoogle Scholar
  24. 24.
    Wiedinger K, Bitsaktsis C, Chang S. Reactivation of human polyomaviruses in immunocompromised states. J Neuro-Oncol. 2014;20:1–8.Google Scholar
  25. 25.
    Chang Y, Moore PS. Merkel cell carcinoma: a virus-induced human cancer. Annu Rev Pathol. 2012;7:123–44.PubMedCrossRefGoogle Scholar
  26. 26.
    Liu W, Yang R, Payne AS, Schowalter RM, Spurgeon ME, Lambert PF, et al. Identifying the target cells and mechanisms of Merkel cell polyomavirus infection. Cell Host Microbe. 2016;19:775–87.PubMedPubMedCentralCrossRefGoogle Scholar
  27. 27.
    Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, D’Angelo SP, et al. Avelumab in patients with chemotherapy-refractory metastatic Merkel cell carcinoma: a multicentre, single-group, open-label, phase 2 trial. Lancet Oncol. 2016;17:1374–85.PubMedPubMedCentralCrossRefGoogle Scholar
  28. 28.
    Wong SQ, Waldeck K, Vergara IA, Schröder J, Madore J, Wilmott JS, et al. UV-associated mutations underlie the etiology of MCV-negative Merkel cell carcinomas. Cancer Res. 2015;75:5228–34.PubMedCrossRefGoogle Scholar
  29. 29.
    Cassler NM, Merrill D, Bichakjian CK, Brownell I. Merkel Cell Carcinoma Therapeutic Update. Curr Treat Options in Oncol. 2016;17:36.CrossRefGoogle Scholar
  30. 30.
    Harms PW, Vats P, Verhaegen ME, Robinson DR, Wu YM, Dhanasekaran SM, et al. The Distinctive mutational spectra of polyomavirus-negative Merkel cell carcinoma. Cancer Res. 2015;75:3720–7.PubMedPubMedCentralCrossRefGoogle Scholar
  31. 31.
    Goh G, Walradt T, Markarov V, Blom A, Riaz N, Doumani R, et al. Mutational landscape of MCPyV-positive and MCPyV-negative Merkel cell carcinomas with implications for immunotherapy. Oncotarget. 2016;7:3403–15.PubMedCrossRefGoogle Scholar
  32. 32.
    Mauzo SH, Ferrarotto R, Bell D, Torres-Cabala CA, Tetzlaff MT, Prieto VG, et al. Molecular characteristics and potential therapeutic targets in Merkel cell carcinoma. J Clin Pathol. 2016;69:382–90.PubMedCrossRefGoogle Scholar
  33. 33.
    Starrett GJ, Marcelus C, Cantalupo PG, Katz JP, Cheng J, Akagi K, et al. Merkel cell polyomavirus exhibits dominant control of the tumor genome and transcriptome in virus-associated Merkel cell carcinoma. MBio. 2017;8:e02079–16.PubMedPubMedCentralCrossRefGoogle Scholar
  34. 34.
    Cohen P, Tomson BN, Elkin SK, Marchlik E, Carter JL, Kurzrock R. Genomic portfolio of Merkel cell carcinoma as determined by comprehensive genomic profiling: implications for targeted therapeutics. Oncotarget. 2016;7:23454–67.PubMedPubMedCentralCrossRefGoogle Scholar
  35. 35.
    Harms PW, Collie AM, Hovelson DH, Cani AK, Verhaegen ME, Patel RM, et al. Next generation sequencing of cytokeratin 20-negative Merkel cell carcinoma reveals ultraviolet-signature mutations and recurrent TP53 and RB1 inactivation. Mod Pathol. 2016;29:240–8.PubMedPubMedCentralCrossRefGoogle Scholar
  36. 36.
    Tai PT, Yu E, Winquist E, Hammond A, Stitt L, Tonita J, et al. Chemotherapy in neuroendocrine/Merkel cell carcinoma of the skin: case series and review of 204 cases. J Clin Oncol. 2000;18:2493–9.PubMedCrossRefGoogle Scholar
  37. 37.
    Tai P, Yu E, Assouline A, Lian JD, Joseph K, Miale T, et al. Multimodality management for 145 cases of Merkel cell carcinoma. Med Oncol. 2010;27:1260–6.PubMedCrossRefGoogle Scholar
  38. 38.
    Shah MH, Varker KA, Collamore M, Zwiebel JA, Coit D, Kelsen D, et al. G3139 (Genasense) in patients with advanced Merkel cell carcinoma. Am J Clin Oncol. 2009;32:174–9.PubMedPubMedCentralCrossRefGoogle Scholar
  39. 39.
    Satpute SR, Ammakkanavar NR, Einhorn LH. Role of platinum-based chemotherapy for Merkel cell tumor in adjuvant and metastatic settings. J Clin Oncol. 2014;32:9049.Google Scholar
  40. 40.
    Iyer JG, Blom A, Doumani R, Lewis C, Tarabadkar ES, Anderson A, et al. Response rates and durability of chemotherapy among 62 patients with metastatic Merkel cell carcinoma. Cancer Med. 2016;5:2294–301.PubMedPubMedCentralCrossRefGoogle Scholar
  41. 41.
    Davids MS, Charlton A, Ng SS, Chong ML, Laubscher K, Dar M, et al. Response to a novel multitargeted tyrosine kinase inhibitor pazopanib in metastatic Merkel cell carcinoma. J Clin Oncol. 2009;27:e97–100.PubMedCrossRefGoogle Scholar
  42. 42.
    Nathan PD, Gaunt P, Wheatley K, Bowden SJ, Savage J, Faust G, et al. UKMCC-01: A phase II study of pazopanib (PAZ) in metastatic Merkel cell carcinoma. J Clin Oncol. 2016;34:9542.CrossRefGoogle Scholar
  43. 43.
    Samlowski WE, Moon J, Tuthill RJ, Heinrich MC, Balzer-Haas NS, Merl SA, et al. A phase II trial of imatinib mesylate in Merkel cell carcinoma (neuroendocrine carcinoma of the skin): A Southwest Oncology Group study (S0331). Am J Clin Oncol. 2010;33:495–9.PubMedPubMedCentralCrossRefGoogle Scholar
  44. 44.
    Fakiha M, Letertre P, Vuillez JP, Lebeau J. Remission of Merkel cell tumor after somatostatin analog treatment. J Cancer Res Ther. 2010;6:382–4.PubMedCrossRefGoogle Scholar
  45. 45.
    Meier G, Waldherr C, Herrmann R, Maecke H, Mueller-Brand J, Pless M. Successful targeted radiotherapy with 90Y-DOTATOC in a patient with Merkel cell carcinoma. Oncology. 2004;66:160–3.PubMedCrossRefGoogle Scholar
  46. 46.
    Salavati A, Prasad V, Schneider C-P, Herbst R, Baum RP. Peptide receptor radionuclide therapy of Merkel cell carcinoma using 177lutetium-labeled somatostatin analogs in combination with radiosensitizing chemotherapy: a potential novel treatment based on molecular pathology. Ann Nucl Med. 2012;26:365–9.PubMedCrossRefGoogle Scholar
  47. 47.
    Luke JJ, Chmura SJ, Allred JB, Salama JK, Al-Hallaq HA, Hsu C, et al. A randomized phase II study of anti-PD1 antibody [MK-3475 (pembrolizumab)] alone versus anti-PD1 antibody plus stereotactic body radiation therapy in advanced Merkel cell carcinoma (Alliance A091605). J Clin Oncol. 2018;36:TPS9599.CrossRefGoogle Scholar
  48. 48.
    Walker J, Kasturi V, Lebbe C, Sandhu SK, Grignani G, Hennessy MG, et al. Second-line avelumab treatment of patients (pts) with metastatic Merkel cell carcinoma (mMCC): Experience from a global expanded access program (EAP). J Clin Oncol. 2018;36:9537.CrossRefGoogle Scholar
  49. 49.
    Tai P. A practical update of surgical management of Merkel cell carcinoma of the skin. ISRN Surg. 2013;2013:850797.PubMedPubMedCentralCrossRefGoogle Scholar
  50. 50.
    Bichakjian CK, Olencki T, Aasi SZ, Alam M, Anderson JS, Blitzblau R, et al. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology (NCCN Guidelines) Merkel Cell Carcinoma. Version 1. 2018. 2017. https://www.nccn.org/professionals/physician_gls/pdf/mcc.pdf. Accessed 20 May 2018.
  51. 51.
    Veness M, Foote M, Gebski V, Poulsen M. The role of radiotherapy alone in patients with Merkel cell carcinoma: reporting the Australian experience of 43 patients. Int J Radiat Oncol Biol Phys. 2010;78:703–9.PubMedCrossRefGoogle Scholar
  52. 52.
    Gunaratne DA, Howle JR, Veness MJ. Definitive radiotherapy for Merkel cell carcinoma confers clinically meaningful in-field locoregional control: A review and analysis of the literature. J Am Acad Dermatol. 2017;77:142–8.PubMedCrossRefGoogle Scholar
  53. 53.
    Mortier L, Mirabel X, Fournier C, Piette F, Lartigau E. Radiotherapy alone for primary Merkel cell carcinoma. Arch Dermatol. 2003;139:1587–90.PubMedCrossRefGoogle Scholar
  54. 54.
    Lewis KG, Weinstock MA, Weaver AL, Otley CC. Adjuvant local irradiation for Merkel cell carcinoma. Arch Dermatol. 2006;142:693–700.PubMedGoogle Scholar
  55. 55.
    Mojica P, Smith D, Ellenhorn JD. Adjuvant radiation therapy is associated with improved survival in Merkel cell carcinoma of the skin. J Clin Oncol. 2007;25:1043–7.PubMedCrossRefGoogle Scholar
  56. 56.
    Kim JA, Choi AH. Effect of radiation therapy on survival in patients with resected Merkel cell carcinoma: a propensity score surveillance, epidemiology, and end results database analysis. JAMA Dermatol. 2013;149:831–8.PubMedCrossRefGoogle Scholar
  57. 57.
    Strom T, Naghavi AO, Messina JL, Kim S, Torres-Roca JF, Russell J, et al. Improved local and regional control with radiotherapy for Merkel cell carcinoma of the head and neck. Head Neck. 2017;39:48–55.PubMedCrossRefGoogle Scholar
  58. 58.
    Jouary T, Leyral C, Dreno B, Doussau A, Sassolas B, Beylot-Barry M, et al. Adjuvant prophylactic regional radiotherapy versus observation in stage I Merkel cell carcinoma: a multicentric prospective randomized study. Ann Oncol. 2012;23:1074–80.PubMedCrossRefGoogle Scholar
  59. 59.
    Bichakjian CK, Harms KL, Schwartz JL. Selective use of adjuvant therapy in the management of Merkel cell carcinoma. JAMA Oncol. 2015;1:1162–3.PubMedCrossRefGoogle Scholar
  60. 60.
    Grotz TE, Joseph RW, Pockaj BA, Foote RL, Otley CC, Bagaria SP, et al. Negative sentinel lymph node biopsy in Merkel cell carcinoma is associated with a low risk of same-nodal-basin recurrences. Ann Surg Oncol. 2015;22(12):4060–6.PubMedCrossRefGoogle Scholar
  61. 61.
    Tsang G, O’Brien P, Robertson R, Hamilton C, Wratten C, Denham J. All delays before radiotherapy risk progression of Merkel cell carcinoma. Australas Radiol. 2004;48:371–5.PubMedCrossRefGoogle Scholar
  62. 62.
    Nghiem P, Kaufman HL, Bharmal M, Mahnke L, Phatak H, Becker JC. Systematic literature review of efficacy, safety and tolerability outcomes of chemotherapy regimens in patients with metastatic Merkel cell carcinoma. Future Oncol. 2017;13:1263–79.PubMedPubMedCentralCrossRefGoogle Scholar
  63. 63.
    Desch L, Kunstfeld R. Merkel cell carcinoma: chemotherapy and emerging new therapeutic options. J Skin Cancer. 2013;2013:327150.PubMedPubMedCentralCrossRefGoogle Scholar
  64. 64.
    Cowey CL, Mahnke L, Espirito J, Helwig C, Oksen D, Bharmal M. Real-world treatment outcomes in patients with metastatic Merkel cell carcinoma treated with chemotherapy in the USA. Future Oncol. 2017;13:1699–710.PubMedCrossRefGoogle Scholar
  65. 65.
    Brunner M, Thurnher D, Pammer J, Geleff S, Heiduschka G, Reinisch CM, et al. Expression of VEGF-A/C, VEGF-R2, PDGF-alpha/beta, c-kit, EGFR, Her-2/Neu, Mcl-1 and Bmi-1 in Merkel cell carcinoma. Mod Pathol. 2008;21:876–84.PubMedCrossRefGoogle Scholar
  66. 66.
    Welsh SJ, Fife K. Pazopanib for the treatment of renal cell carcinoma. Future Oncol. 2015;11:1169–79.PubMedCrossRefGoogle Scholar
  67. 67.
    Mita M, Tolcher AW. Novel apoptosis inducing agents in cancer therapy. Curr Probl Cancer. 2005;29:8–32.PubMedCrossRefGoogle Scholar
  68. 68.
    Schlagbauer-Wadl H, Klosner G, Heere-Ress E, Waltering S, Moll I, Wolff K, et al. Bcl-2 antisense oligonucleotides (G3139) inhibit Merkel cell carcinoma growth in SCID mice. J Invest Dermatol. 2000;114:725–73.PubMedCrossRefGoogle Scholar
  69. 69.
    Scarpa A, Chang DK, Nones K, Corbo V, Patch AM, Bailey P, et al. Whole-genome landscape of pancreatic neuroendocrine tumours. Nature. 2017;543:65–71.CrossRefGoogle Scholar
  70. 70.
    Isakoff SJ, Puhalla S, Domchek SM, Friedlander M, Kaufman B, Robson M, et al. A randomized Phase II study of veliparib with temozolomide or carboplatin/paclitaxel versus placebo with carboplatin/paclitaxel in BRCA1/2 metastatic breast cancer: design and rationale. Future Oncol. 2017;13:307–20.CrossRefPubMedGoogle Scholar
  71. 71.
    Nardi V, Song Y, Santamaria-Barria JA, Cosper AK, Lam Z, Faber AC, et al. Activation of PI3K signaling in Merkel cell carcinoma. Clin Cancer Res. 2012;18:1227–36.PubMedPubMedCentralCrossRefGoogle Scholar
  72. 72.
    Papotti M, Macri’ L, Pagani A, Aloi F, Bussolati G. Quantitation of somatostatin receptor type 2 in neuroendocrine (Merkel cell) carcinoma of the skin by competitive RT-PCR. Endocr Pathol. 1999;10:37–46.CrossRefGoogle Scholar
  73. 73.
    Bhatia S, Afanasiev O, Nghiem P. Immunobiology of Merkel cell carcinoma: implications for immunotherapy of a polyomavirus-associated cancer. Curr Oncol Rep. 2011;13:488–97.PubMedPubMedCentralCrossRefGoogle Scholar
  74. 74.
    Lyngaa R, Pedersen NW, Schrama D, Thrue CA, Ibrani D, Met O, et al. T-cell responses to oncogenic Merkel cell polyomavirus proteins distinguish patients with Merkel cell carcinoma from healthy donors. Clin Cancer Res. 2014;20:1768–78.PubMedPubMedCentralCrossRefGoogle Scholar
  75. 75.
    Iyer JG, Afanasiev OK, McClurkan C, Paulson K, Nagase K, Jing L, et al. Merkel cell polyomavirus-specific CD8+ and CD4+ T-cell responses identified in Merkel cell carcinomas and blood. Clin Cancer Res. 2011;17:6671–80.PubMedPubMedCentralCrossRefGoogle Scholar
  76. 76.
    Miller NJ, Church CD, Dong L, Crispin D, Fitzgibbon MP, Lachance K, et al. Tumor-infiltrating Merkel cell polyomavirus-specific T cells are diverse and associated with improved patient survival. Cancer Immunol Res. 2017;5:137–47.PubMedPubMedCentralCrossRefGoogle Scholar
  77. 77.
    Behr DS, Peitsch WK, Hametner C, Lasitschka F, Houben R, Schönhaar K, et al. Prognostic value of immune cell infiltration, tertiary lymphoid structures and PD-L1 expression in Merkel cell carcinomas. Int J Clin Exp Pathol. 2014;7:7610–21.PubMedPubMedCentralGoogle Scholar
  78. 78.
    Walsh NM, Fleming KE, Hanly JG, Dakin Hache K, Doucette S, Ferrara G, et al. A morphological and immunophenotypic map of the immune response in Merkel cell carcinoma. Hum Pathol. 2016;52:190–6.PubMedCrossRefGoogle Scholar
  79. 79.
    Afanasiev OK, Yelistratova L, Miller N, Nagase K, Paulson K, Iyer JG, et al. Merkel polyomavirus specific T cells fluctuate with Merkel cell carcinoma burden and express therapeutically targetable PD-1 and Tim-3 exhaustion markers. Clin Cancer Res. 2013;19:5351–60.PubMedPubMedCentralCrossRefGoogle Scholar
  80. 80.
    Paulson KG, Tegeder A, Willmes C, Iyer JG, Afanasiev OK, Schrama D, et al. Downregulation of MHC-I expression is prevalent but reversible in Merkel cell carcinoma. Cancer Immunol Res. 2014;2:1071–9.PubMedPubMedCentralCrossRefGoogle Scholar
  81. 81.
    Ritter C, Fan K, Paschen A, Reker Hardrup S, Ferrone S, Nghiem P, et al. Epigenetic priming restores the HLA class-I antigen processing machinery expression in Merkel cell carcinoma. Sci Rep. 2017;7:2290.PubMedPubMedCentralCrossRefGoogle Scholar
  82. 82.
    Zitvogel L, Kroemer G. Targeting PD-1/ PD-L1 interactions for cancer immunotherapy. Oncoimmunology. 2012;1:1223–5.PubMedPubMedCentralCrossRefGoogle Scholar
  83. 83.
    Lipson EJ, Vincent JG, Loyo M, Kagohara LT, Luber BS, Wang H, et al. PD-L1 expression in the Merkel cell carcinoma microenvironment: association with inflammation, Merkel cell polyomavirus and overall survival. Cancer Immunol Res. 2013;1:54–63.PubMedCrossRefGoogle Scholar
  84. 84.
    Garbe C, Eigentler TK, Keilholz U, Hauschild A, Kirkwood JM. Systematic review of medical treatment in melanoma: current status and future prospects. Oncologist. 2011;16:5–24.PubMedPubMedCentralCrossRefGoogle Scholar
  85. 85.
    Chapuis AG, Afanasiev OK, Iyer JG, Paulson KG, Parvathaneni U, Hwang JH, et al. Regression of metastatic Merkel cell carcinoma following transfer of polyomavirus-specific T cells and therapies capable of re-inducing HLA class-I. Cancer Immunol Res. 2014;2:27–36.PubMedCrossRefGoogle Scholar
  86. 86.
    Arora R, Chang Y, Moore PS. MCV and Merkel cell carcinoma: a molecular success story. Curr Opin Virol. 2012;2:489–98.PubMedPubMedCentralCrossRefGoogle Scholar
  87. 87.
    Veija T, Sarhadi VK, Koljonen V, Bohling T, Knuutila S. Hotspot mutations in polyomavirus positive and negative Merkel cell carcinomas. Cancer Genet. 2016;209:30–5.PubMedCrossRefGoogle Scholar
  88. 88.
    Vandeven N, Nghiem P. Rationale for immune-based therapies in Merkel polyomavirus-positive and negative Merkel cell carcinomas. Immunotherapy. 2016;8:907–21.PubMedPubMedCentralCrossRefGoogle Scholar
  89. 89.
    Paulson KG, Lewis CW, Redman MW, Simonson WT, Lisberg A, Ritter D, et al. Viral oncoprotein antibodies as a marker for recurrence of Merkel cell carcinoma: A prospective validation study. Cancer. 2017;123:1464–74.PubMedCrossRefGoogle Scholar
  90. 90.
    Samimi M, Molet L, Fleury M, Laude H, Carlotti A, Gardair C, et al. Prognostic value of antibodies to Merkel cell polyomavirus T antigens and VP1 protein in patients with Merkel cell carcinoma. Br J Dermatol. 2016;174:813–22.PubMedCrossRefGoogle Scholar
  91. 91.
    Dowlatshahi M, Huang V, Gehad AE, Jiang Y, Calarese A, Teague JE, et al. Tumor-specific T cells in human Merkel cell carcinomas: a possible role for Tregs and T-cell exhaustion in reducing T-cell responses. J Invest Dermatol. 2013;133:1879–89.PubMedPubMedCentralCrossRefGoogle Scholar
  92. 92.
    Sihto H, Kukko H, Koljonen V, Sankila R, Böhling T, Joensuu H. Clinical factors associated with Merkel cell polyomavirus infection in Merkel cell carcinoma. J Natl Cancer Inst. 2009;101:938–45.PubMedCrossRefGoogle Scholar
  93. 93.
    Feldmeyer L, Hudgens CW, Ray-Lyons G, Nagarajan P, Aung PP, Curry JL, et al. Density, distribution, and composition of immune infiltrates correlate with survival in Merkel cell carcinoma. Clin Cancer Res. 2016;22:5553–63.PubMedPubMedCentralCrossRefGoogle Scholar
  94. 94.
    Walocko FM, Scheier BY, Harms PW, Fecher LA, Lao CD. Metastatic Merkel cell carcinoma response to nivolumab. J Immunother Cancer. 2016;4:79.PubMedPubMedCentralCrossRefGoogle Scholar
  95. 95.
    Shimizu T, Seto T, Hirai F, Takenoyama M, Nosaki K, Tsurutani J, et al. Phase 1 study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody) in Japanese patients with advanced solid tumors. Investig New Drugs. 2016;34:347–54.CrossRefGoogle Scholar
  96. 96.
    Patnaik A, Kang SP, Rasco D, Papadopoulos KP, Elassaiss-Schaap J, Beeram M, et al. Phase I study of pembrolizumab (MK-3475; anti-PD-1 monoclonal antibody in patients with advanced solid tumors). Clin Cancer Res. 2015;21:4286–93.PubMedCrossRefGoogle Scholar
  97. 97.
    Nghiem PT, Bhatia S, Lipson EJ, Kudchadkar RR, Miller NJ, Annamalai L, et al. PD-1 blockade with pembrolizumab in advanced Merkel-cell carcinoma. N Engl J Med. 2016;374:2542–52.PubMedPubMedCentralCrossRefGoogle Scholar
  98. 98.
    Nghiem P, Bhatia S, Lipson EJ, Sharfman WH, Kudchadkar RR, Friedlander PA, et al. Durable tumor regression and overall survival (OS) in patients with advanced Merkel cell carcinoma (aMCC) receiving pembrolizumab as first-line therapy. J Clin Oncol. 2018;36:9506.CrossRefGoogle Scholar
  99. 99.
    Bavencio (avelumab) injection [package insert]. Darmstadt, Germany: Merck KGaA. 2017. https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/761049s000lbl.pdf. Accessed 15 July 2018.
  100. 100.
    European Commission approves Bavencio (avelumab) for metastatic Merkel cell carcinoma. Darmstadt: Merck KGaA and Pfizer Inc. 2017. https://www.pfizer.com/news/press-release/press-release-detail/european_commission_approves_bavencio_avelumab_for_metastatic_merkel_cell_carcinoma. Accessed 15 July 2018.
  101. 101.
    Bavencio (avelumab) approved for Merkel cell carcinoma in Japan. Darmstadt, Germany: Merck KGaA and Pfizer Inc; September 21, 2017. https://www.pfizer.com/news/press-release/press-release-detail/bavencio_avelumab_approved_for_merkel_cell_carcinoma_in_japan. Accessed 15 July 2018.
  102. 102.
    Kaufman HL, Russell J, Hamid O, Bhatia S, Terheyden P, D’Angelo SP, et al. Updated efficacy of avelumab in patients with previously treated metastatic Merkel cell carcinoma after ≥1 year of follow-up: JAVELIN Merkel 200, a phase 2 clinical trial. J Immunother Cancer. 2018;6:7.PubMedPubMedCentralCrossRefGoogle Scholar
  103. 103.
    Nghiem P, Bhatia S, Brohl AS, Hamid O, Mehnert JM, Terheyden P, et al. Two-year efficacy and safety update from JAVELIN Merkel 200 part A: A registrational study of avelumab in metastatic Merkel cell carcinoma progressed on chemotherapy. J Clin Oncol. 2018;36:9507.CrossRefGoogle Scholar
  104. 104.
    D’Angelo SP, Russell J, Lebbé C, Chmielowski B, Gambichler T, Grob JJ, et al. Efficacy and safety of first-line avelumab treatment in patients with stage IV metastatic Merkel cell carcinoma: a preplanned interim analysis of a clinical trial. JAMA Oncol. 2018;  https://doi.org/10.1001/jamaoncol.2018.0077.PubMedPubMedCentralCrossRefGoogle Scholar
  105. 105.
    Topalian SL, Bhatia S, Kudchadkar RR, Amin A, Sharfman WH, Lebbe C, et al. Nivolumab (Nivo) as neoadjuvant therapy in patients with resectable Merkel cell carcinoma (MCC) in CheckMate 358. J Clin Oncol. 2018;36:9505.CrossRefGoogle Scholar
  106. 106.
    Hodi FS, O’Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB, et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med. 2010;363:711–23.PubMedPubMedCentralCrossRefGoogle Scholar
  107. 107.
    Eggermont AM, Chiarion-Sileni V, Grob JJ, Dummer R, Wolchok JD, Schmidt H, et al. Adjuvant ipilimumab versus placebo after complete resection of high-risk stage III melanoma (EORTC 18071): a randomised, double-blind, phase 3 trial. Lancet Oncol. 2015;16:522–30.PubMedCrossRefGoogle Scholar
  108. 108.
    Becker JC, Hassel JC, Menzer C, Kähler KC, Eigentler TK, Meier FE, et al. Adjuvant ipilimumab compared with observation in completely resected Merkel cell carcinoma (ADMEC): A randomized, multicenter DeCOG/ADO study. J Clin Oncol. 2018;36:9527.CrossRefGoogle Scholar
  109. 109.
    Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455–65.PubMedPubMedCentralCrossRefGoogle Scholar
  110. 110.
    Wolchok JD, Neyns B, Linette G, Negrier S, Lutzky J, Thomas L, et al. Ipilimumab monotherapy in patients with pretreated advanced melanoma: a randomised, double-blind, multicentre, phase 2, dose-ranging study. Lancet Oncol. 2010;11:155–64.CrossRefPubMedGoogle Scholar
  111. 111.
    Rudmann DG. On-target and off-target-based toxicologic effects. Toxicol Pathol. 2013;41:310–4.PubMedCrossRefGoogle Scholar
  112. 112.
    Spain L, Diem S, Larkin J. Management of toxicities of immune checkpoint inhibitors. Cancer Treat Rev. 2016;44:51–60.PubMedCrossRefGoogle Scholar
  113. 113.
    Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–64.PubMedPubMedCentralCrossRefGoogle Scholar
  114. 114.
    Davies M. New modalities of cancer treatment for NSCLC: focus on immunotherapy. Cancer Manag Res. 2014;6:63–75.PubMedPubMedCentralCrossRefGoogle Scholar
  115. 115.
    Wolchok JD, Kluger H, Callahan MK, Postow MA, Rizvi NA, Lesokhin AM, et al. Nivolumab plus ipilimumab in advanced melanoma. N Engl J Med. 2013;369:122–33.PubMedPubMedCentralCrossRefGoogle Scholar
  116. 116.
    Weber JS, Yang JC, Atkins MB, Disis ML. Toxicities of Immunotherapy for the Practitioner. J Clin Oncol. 2015;33:2092–9.PubMedPubMedCentralCrossRefGoogle Scholar
  117. 117.
    Larkin J, Hodi FS, Wolchok JD. Combined Nivolumab and Ipilimumab or monotherapy in untreated melanoma. N Engl J Med. 2015;373:1270–1.PubMedCrossRefGoogle Scholar
  118. 118.
    Harrington KJ, Puzanov I, Hecht JR, Hodi FS, Szabo Z, Murugappan S, et al. Clinical development of talimogene laherparepvec (T-VEC): a modified herpes simplex virus type-1-derived oncolytic immunotherapy. Expert Rev Anticancer Ther. 2015;15:1389–403.PubMedCrossRefGoogle Scholar
  119. 119.
    Poulsen MG, Rischin D, Porter I, Walpole E, Harvey J, Hamilton C, et al. Does chemotherapy improve survival in high-risk stage I and II Merkel cell carcinoma of the skin? Int J Radiat Oncol Biol Phys. 2006;64:114–9.PubMedCrossRefGoogle Scholar
  120. 120.
    Triozzi PL, Fernandez AP. The role of the immune response in Merkel cell carcinoma. Cancers (Basel). 2013;5:234–54.CrossRefGoogle Scholar
  121. 121.
    Vandeven NA, Nghiem P. Merkel cell carcinoma: An unusually immunogenic cancer proves ripe for immune therapy. J Oncol Pract. 2016;12:649–50.PubMedPubMedCentralCrossRefGoogle Scholar
  122. 122.
    Melero I, Navarro B, Teijeira A, Coukos G. Cancer immunotherapy full speed ahead. Ann Oncol. 2017;28:xii1–2.PubMedCrossRefGoogle Scholar
  123. 123.
    Liu D, Li G, Avella DM, Kimchi ET, Kaifi JT, Rubinstein MP, et al. Sunitinib represses regulatory T cells to overcome immunotolerance in a murine model of hepatocellular cancer. Oncoimmunology. 2017;7:e1372079.PubMedPubMedCentralCrossRefGoogle Scholar

Copyright information

© Springer Nature Switzerland AG 2018

Authors and Affiliations

  • Daniela Femia
    • 1
  • Natalie Prinzi
    • 1
  • Andrea Anichini
    • 2
  • Roberta Mortarini
    • 2
  • Federico Nichetti
    • 1
  • Francesca Corti
    • 1
  • Martina Torchio
    • 1
  • Giorgia Peverelli
    • 1
  • Filippo Pagani
    • 1
  • Andrea Maurichi
    • 3
  • Ilaria Mattavelli
    • 3
  • Massimo Milione
    • 4
  • Nice Bedini
    • 5
  • Ambra Corti
    • 6
  • Maria Di Bartolomeo
    • 1
  • Filippo de Braud
    • 1
    • 7
  • Sara Pusceddu
    • 1
  1. 1.Department of Medical Oncology Unit-1Fondazione IRCCS Istituto Nazionale dei Tumori di Milano and ENETS Center of ExcellenceMilanItaly
  2. 2.Department of Research, Human Tumors Immunobiology UnitFondazione IRCCS Istituto Nazionale dei Tumori, Milano and ENETS Center of ExcellenceMilanItaly
  3. 3.Melanoma and Sarcoma UnitFondazione IRCCS Istituto Nazionale dei Tumori, ENETS Center of ExcellenceMilanItaly
  4. 4.1st Pathology Division, Department of Pathology and Laboratory MedicineFondazione IRCCS Istituto Nazionale dei Tumori and ENETS Center of ExcellenceMilanItaly
  5. 5.Radiation Oncology 1Fondazione IRCCS Istituto Nazionale dei Tumori, Milano and ENETS Center of ExcellenceMilanItaly
  6. 6.PolistudiumMilanItaly
  7. 7.University of MilanMilanItaly

Personalised recommendations